The global liposomal drugs market is expected to witness significant growth during the forecast period. Liposomes help in delivering drugs by the process of diffusion rather than by direct cell fusion. They enable a diverse range of drugs that is encapsulated by these vesicles, which contributes to the growth of the global market. The increasing incidence of fungal disorders is prompting a lot in increasing the demand for liposomal formulations of Amphotericin B. Thus, it helps in leading the market growth.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphoteracin B, Others), Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Ocular and Pulmonary), Industry (Pharmaceutical, Cosmetic, Food, Farming) – Industry Trends and Forecast to 2032.
.
The Global Liposomal Drugs Market size was valued at USD 5.31 USD Billion in 2024.
The Global Liposomal Drugs Market is projected to grow at a CAGR of 8.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
